Royal College of Surgeons in Ireland
Browse

Phenotypic outcomes of PKD1 compared with non-PKD1 genetically confirmed autosomal dominant polycystic kidney disease

journal contribution
posted on 2025-03-07, 13:18 authored by Elhussein ElhassanElhussein Elhassan, Darragh O'Donoghue, Sophia HeneghanSophia Heneghan, Omri TeltshOmri Teltsh, Sahin SarihanSahin Sarihan, Shohdan OsmanShohdan Osman, Michelle Clince, David Synnott, Sophie Craig, Amy Hudson, Brendan DoyleBrendan Doyle, David Lappin, Donal J Sexton, Liam Casserly, John Holian, Colm Magee, Mark Denton, Clodagh Sweeney, Atif AwanAtif Awan, Emma McCann, Gianpiero CavalleriGianpiero Cavalleri, Katherine Benson, Peter ConlonPeter Conlon

Background: Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the most common monogenic cause of kidney failure. While identifying genetic variants predicts disease progression, characterization of recently described ADPKD-like variants is limited. We explored disease progression and genetic spectrum of genetically-confirmed ADPKD families with PKD1 and non-PKD1 variants.

Methods: In this observational study, we evaluated the clinical (ADPKD-related complications, estimated glomerular filtration rate (eGFR) decline, and progression to kidney failure), radiological (height-adjusted total kidney volume (ht-TKV)), and genetic characteristics of ADPKD families referred to the Irish Kidney Gene Project. Logistic regression and Kaplan-Meier analyses examined relationships between genetic variants and disease progression.

Results: Genomic sequencing was performed on 261 ADPKD families, and 75.8% (198/261 families, comprising 391 individuals) were identified to harbor pathogenic/likely pathogenic variants; 74.2% (147/198) PKD1 families and 23.2% (46/198) non-PKD1 families, which include PKD2 (n = 29 families), IFT140 variants (n = 4), ALG5, DNAJB11 and NEK8 (n = 3 each), ALG8 and ALG9 variants (n = 2 each). The remaining 2.6% (5/198) accounted for non-ADPKD variants.

Compared to PKD1, non-PKD1 families were characterized by a milder phenotype; milder eGFR decline (- 1.4 mL/min/1.73m2/year vs. - 3.2; p < 0.001), smaller ht-TKV (449.7 mL/m vs. 1769; p 0.002) and a delayed progression towards kidney failure (73 vs. 52 years; HR: 0.12, p < 0.001 [95% CI: 0.07-0.19]). ADPKD-NEK8 heterozygotes demonstrated earlier progression to kidney failure (average age 8 vs. 49 years for PKD1; Bonferroni-corrected p 0.017).

Conclusion: Non-PKD1 variants have heterogeneous phenotypic and genotypic attributes resulting in milder disease, although ADPKD-NEK8 is an important exception with early progression.

Funding

Royal College of Surgeons in Ireland StAR PhD

The Health Research Board funded the Irish Kidney Gene Project under the HRCI-HRB Joint funding scheme (Grant code: HRCI-HRB-2020-032)

BioMarin

HRB research Grant and funding from BioMarin Pharmaceutical

Informing Chronic Kidney Disease health policy in Ireland: Linkage of large datasets to study the interaction between ageing and kidney function

Health Research Board

Find out more...

History

Data Availability Statement

The data underlying this article will be shared on reasonable request to the corresponding author.

Comments

This version of the article has been accepted for publication, after peer review and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s40620-024-02184-3

Published Citation

Elhassan EAE, et al. Phenotypic outcomes of PKD1 compared with non-PKD1 genetically confirmed autosomal dominant polycystic kidney disease. J Nephrol. 2025.

Publication Date

30 January 2025

PubMed ID

39881088

Department/Unit

  • Beaumont Hospital
  • FutureNeuro Centre
  • Medicine
  • Pathology
  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Immunity, Infection and Inflammation

Publisher

Springer Nature

Version

  • Accepted Version (Postprint)